Zobrazeno 1 - 10
of 170
pro vyhledávání: '"focal‐onset seizures"'
Autor:
Sangeeta Ravat, Anshu Rohatgi, Rahul Kulkarni, Shaik A. Jabeen, Balaji Patil, Amitabh Dash, Manoj Malhotra
Publikováno v:
Epilepsia Open, Vol 9, Iss 3, Pp 940-950 (2024)
Abstract Objective ESPRITE (Study 508; NCT03836924) evaluated the real‐world safety, tolerability, and efficacy of adjunctive perampanel in patients aged ≥12 years with focal‐onset seizures (FOS), with or without focal to bilateral tonic–clon
Externí odkaz:
https://doaj.org/article/53a7fbc76d764f7caf95cd712768f626
Autor:
Takuji Nishida, Sang Kun Lee, Yushi Inoue, Kazunori Saeki, Kohei Ishikawa, Manoj Malhotra, Anna Patten, Sunao Kaneko
Publikováno v:
Epilepsia Open, Vol 9, Iss 2, Pp 501-512 (2024)
Abstract Objective To evaluate the long‐term efficacy, safety, and tolerability of adjunctive perampanel for the treatment of patients with refractory focal‐onset seizures (FOS), with or without focal to bilateral tonic–clonic seizures (FBTCS),
Externí odkaz:
https://doaj.org/article/28c8e4f9548e474aaf62d790a40c4b6c
Autor:
Haiyan Ma, Haitao Zhu, Fangqing Chen, Yiqing Yang, Xuefeng Qu, Honghao Xu, Lu Yang, Rui Zhang
Publikováno v:
Epilepsia Open, Vol 8, Iss 4, Pp 1474-1483 (2023)
Abstract Objective Efficacy and safety of perampanel monotherapy for treating focal‐onset seizures (FOS) has been barely studied in China. This observational study aimed to evaluate the efficacy and safety of perampanel monotherapy in treating Chin
Externí odkaz:
https://doaj.org/article/56bd9dc982394a9fb65d774fbd6ba7ad
Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy
Autor:
Ryosuke Hanaya, Yuichi Kubota, Masahiro Mizobuchi, Koji Iida, Tomonori Ono, Hiromichi Motooka, Naoki Nakano, Ayataka Fujimoto, Masaki Iwasaki, Masafumi Fukuda, Akihiko Kondo, Katsuhisa Uruno, Shintaro Yamamuro, Kohei Yamaguchi, Kisaki Onishi, Leock Y Ngo, Yushi Inoue
Publikováno v:
Epilepsia Open, Vol 8, Iss 4, Pp 1369-1382 (2023)
Abstract Objective Perampanel is an oral anti‐seizure medication, which is approved in Japan for focal‐onset seizures, with/without focal to bilateral tonic–clonic seizures, as monotherapy/adjunctive therapy in patients aged 4 years and older.
Externí odkaz:
https://doaj.org/article/d4e415cc099a4f0782e716075c0be65b
Autor:
Nicola Pietrafusa, Giovanni Falcicchio, Emilio Russo, Simona Lattanzi, Bianca Goffredo, Raffaele Simeoli, Sara Cairoli, Tiziana Corsetti, Roberta Roberti, Marina De Tommaso, Federico Vigevano, Angela La Neve, Nicola Specchio
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Cenobamate (CNB) is an anti-seizure medication (ASM) approved in 2021 in Europe for adjunctive treatment of focal-onset seizures in adults who were not adequately controlled with at least two previous ASMs.Methods: seizure outcome, treatm
Externí odkaz:
https://doaj.org/article/9c5993e6d1dd47cba23648716cd6dd48
Autor:
Lehong Gao, Qiang Lu, Zan Wang, Wei Yue, Guoping Wang, Xiaoqiu Shao, Yi Guo, Yonghong Yi, Zhen Hong, Yuwu Jiang, Bo Xiao, Guiyun Cui, Feng Gao, Jiasheng Hu, Jianmin Liang, Meiyun Zhang, Yuping Wang
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundNo interventional study has been conducted in China to assess efficacy and safety of perampanel in treating Chinese patients with epilepsy, nor has there been any study on perampanel early add-on therapy in China. This interventional study
Externí odkaz:
https://doaj.org/article/f006c92e812a42afaf4c7e5baaef7155
Autor:
TingtingYang, CuihuaYan, Tao Han, Huai kuanWu, JunjiHu, YujiaoWu, Yang Jin, Jing Jiang, Xue wuLiu
Publikováno v:
Heliyon, Vol 9, Iss 7, Pp e17384- (2023)
Background: To evaluate the efficacy and safety of zonisamide (ZNS) as the first additional treatment for focal or secondarily bilateral tonic–clonic seizure (sBTCS). Methods: A total of 118 patients between 18 and 75 years of age with focal or sBT
Externí odkaz:
https://doaj.org/article/ac0fbdc28bf5465da43bbaa01df1002e
Publikováno v:
Epilepsia Open, Vol 7, Iss 2, Pp 271-279 (2022)
Abstract Objective The last decade has seen an increase in the use of anti‐seizure medications (ASMs); however, the burden of treating drug‐resistant epilepsy has not fallen. We performed this meta‐analysis to evaluate the optimal dose of Peram
Externí odkaz:
https://doaj.org/article/ae939330a10d4ee8a0bb8fc98f7b81b1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.